Compare APT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | SER |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 42.0M |
| IPO Year | 1997 | 2024 |
| Metric | APT | SER |
|---|---|---|
| Price | $5.46 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 41.4K | 40.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $59,142,000.00 | $130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | 2.25 | ★ 132.14 |
| 52 Week Low | $4.34 | $1.22 |
| 52 Week High | $7.50 | $7.92 |
| Indicator | APT | SER |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 74.64 |
| Support Level | $5.49 | $1.74 |
| Resistance Level | $5.69 | $2.99 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 91.18 | 90.91 |
Alpha Pro Tech Ltd is in the business of protecting people, products, and environments. It is developing, manufacturing, and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical, and dental markets. It also manufactures a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply, consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment, and synthetic roof underlayment accessories.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.